Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-10-11
2005-10-11
Hayes, Robert C. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388240
Reexamination Certificate
active
06953842
ABSTRACT:
Novel 2 polypeptides with binding affinity for the p185HER2receptor, designated heregulin 2-α and heregulin 2-β, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-α has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-α useful in the production of heregulin 2-α by recombinant means. Further provided an amino acid sequence of heregulin 2-α and heregulin 2-β. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4882275 (1989-11-01), Klagsburn
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5169837 (1992-12-01), Lagarde et al.
patent: 5237056 (1993-08-01), Fischbach
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5464751 (1995-11-01), Greene et al.
patent: 5578482 (1996-11-01), Lippman et al.
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 5641869 (1997-06-01), Vandlen et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 505148 (1992-09-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 91/15230 (1991-10-01), None
patent: WO 91/18921 (1991-12-01), None
patent: WO 92/00595 (1992-04-01), None
patent: WO 92/12174 (1992-07-01), None
patent: WO 92/18627 (1992-10-01), None
patent: WO 93/22339 (1993-11-01), None
patent: WO 93/22424 (1993-11-01), None
patent: WO 98/02541 (1998-01-01), None
Geyser et al. J. Molecular Recognition 1:32-41, 1988.
Maniatis et al.,Molecular Cloning: A Laboratory Manual, 1st edition, NY Cold Spring Harbor Lab, Chaps. 11 and 12, pp. 404-406, 431-433, 11.2-11.19, 11.44-11.49, 11.52-11.53, 11.58-11.61 (1982).
Bargmann et al., “Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p185”Cell45:649-657 (Jun. 6, 1986).
Benveniste et al., “Purification and characterization of a human T-lymphocyte-derived glial growth-promoting factor”Proc. Natl. Acad. Sci.82:3930-3934 (1985).
Brockes et al., “Glial growth factor-like activity in Schwann Cell tumors”Annals of Neurology20:317-322 (1986).
Brockes et al., “Purification and preliminary characterization of a glial growth factor from the bovine pituitary”Journal of Biological Chemistry255(18):8374-8377 (1980).
Brockes, “Assay and isolation of glial growth factor from the bovine pituitary”Methods in Enzymology147:217-225 (1987).
Cohen, J.A. et al., “Expression of the neu proto-oncogene by Schwann Cells during peripheral nerve development and Wallerian degeneration”J. Neuroscience Res.31:622-634 (1992).
Davis et al., “Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned medium”Biochem.&Biophys. Res. Comm.179(3):1536-1542 (1991).
Davis et al., “Platelet-derived growth factors and fibroblast growth factors are mitogens for rat Schwann Cells”Journal of Cell Biology110:1353-1360 (1990).
De Corte et al., “A 50 kDa protein present in conditioned medium of COLO-16 cells stimulates cell spreading and motility, and activates tyrosine phosphorylation of Neu/HER-2, in human SK-BR-3 mammary cancer cells”J. Cell Science107:405-416 (1994).
Dobashi et al., “Characterization of a neu/c-erbB-2 protein-specific activating factor”Proc. Natl. Acad. Sci.88:8582-8596 (1991).
Falls et al., “ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the Neu ligand family”Cell72:801-815 (1993).
Fitzgerald et al., “Characterization and Sequence Analysis of the Human Ornithine Decarboxylase Gene”DNA8 (9):623-634 (1989).
Gray et al., “Nucleotide sequence of epidermal growth factor cDNA predicts a 128,000-molecular weight protein precursor”Nature303:722-725 (1983).
Groenen et al., “Structure-Function Relationships for the EGF/TGF-α Family of Mitogens”Growth Factors11:235-257 (1994).
Hoffman, Michelle, “New Clue Found to Oncogene's Role in Breast Cancer”Science256:1129 (1992).
Holmes et al., “Identification of Heregulin, A Specific Activator of p185erbB2”Science256:1205-1210 (May 22, 1992).
Hudziak et al., “p185HER2Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor”Molecular&Cellular Biology9(3):1165-1172 (Mar. 1989).
Kimura et al., “Structure, expression and function of a schwannoma-derived growth factor”Nature348:257-260 (1990).
Kokai et al., “Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products”Proc. Natl. Acad. Sci USA85:5389-5393 (1988).
Kunisada et al., “Sequence Organization of Repetitive Sequences Enriched in Small Polydisperse Circular DNAs from HeLa Cells”J. Mol. Biol.198:557-565 (1987).
Lemke & Brockes, “Identification and purification of glial growth factor”J. Neurosci.4(1):75-83 (1984).
Lupu et al., “Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2”Science249:1552-1555 (1990).
Lupu et al., “Purification and Characterization of a Novel Growth Factor from Human Breast Cancer Cells”Biochemistry31:7330-7340 (1992).
Lupu et al., “Purification of a novel growth factor that binds exclusively to the erbB-2 receptor protein and induces cellular responses”Proc. Am. Assoc. Cancer Res.32:abst. No. 297, p. 50 (1991).
Marchionni et al., “Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system”Nature362:312-318 (1993).
Nagata et al., “Solution structure of the epidermal growth factor-like domain of heregulin-α, a ligand for p185erbB-4”EMBO J,13(15):3517-3523 (1994).
Peles et al., “Isolation of the Neu/HER-2 Stimulatory Ligand: A 44 Kd Glycoprotein That Induces Differentiation of Mammary Tumor Cells”Cell69(1):205-216 (1992).
Pohlenz et al., “The Human VK Locus, Characterization of Extended Immunoglobulin Gene Regions by Cosmid Cloning”J. Mol. Biol.193:241-253 (1987).
Sliwkowski et al., “Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin”Journal of Biological Chemistry269(20):14661-14665 (May 20, 1994).
Tarakhovsky et al., “A 25 Kda polypeptide is the ligand for p185Neu and is secreted by activated macrophages”Oncogene6(12):2187-2196 (1991).
Trachtenberg et al., “Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor”Nature379:174-177 (1996).
Wen et al., “Neu differentiation factor: a transmembrane glycoprotein containing an EGF Domain and an Immunoglobulin Homology Unit”Cell69(3):559-572 (1992).
Xu et al.Eighty-Second Annual Meeting of the American Association for Cancer Research Proceedings32:260 (Abstract No. 1544 1991).
Yarden et al., “Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene”Proc. Natl. Acad. Sci. USA86:3179-3183 (1989).
Yarden, “Biochemical Analysis of the Ligand for the neu Oncogenic Receptor”Biochemistry30:3543-3550 (1991).
Nosoh et al., “Protein Stability and Stabilization through Protein Engineering”,New York, New York: Ellis Horwood Ltd., pp. 26, 27, 55-56, 62, 143, 180 (1991).
Holmes William E.
Vandlen Richard L.
Genentech Inc.
Hayes Robert C.
Merchant & Gould P.C.
LandOfFree
Antibodies to heregulin 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to heregulin 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to heregulin 2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467792